When a company has a portfolio of promising assets in development, there are a set of difficult choices to make. Each asset has the potential to be the next ‘big product’ and has a team of excited people supporting it. How can you pick the likely winners from the losers with so many different and conflicting opinions?

Despite our best attempts at being data-based, sometimes the process can feel like buying a product online based only on a few reviews. Each person in the room presents a preview of how ‘amazing’ their asset is, and the decision is made based on how well they argue.

当您只承诺使用新的烹饪小工具时，这种方法可能会起作用，但是当该决定定义公司的未来时，这将成为一个真正的问题。这些基于直觉的决策方法的原因常常（例如基于直觉的本能，宠物项目和有限的经验来决定）是由于无法获得良好的信息。行业信息分散或难以解释，即使是过去项目的相关公司数据也经常被孤立的团队孤立和管理。这意味着决策者很少在一个地方拥有所需的所有信息来做出最佳的投资决策。

更好的数据，更好的决定

为了增加公司成功的机会，您需要更好的数据，类似物和分析工具来提出正确的答案。这是许多制药投资组合团队不足的地方，使重量重量是本能的，而不是更深入地挖掘数据。所有基于有限经验的决策都为药物开发过程增加了风险和不确定性，这是药物如此昂贵的原因的一部分。

With the average launched drug cost now around26亿美元，以及新资产的批准率约为12％，对这些决定的正确做法比以往任何时候都重要。

如今，最好的制药公司越来越多地利用大量富裕和细微的现实世界数据来告知其关键的行为/不进行决策。综上所述，这些数据可以更准确地预测特定药物需要开发的时间，试验将花费多少，目标患者人群的大小以及更多。它还可以告诉您哪些竞争项目可能在市场上具有最大的影响力，哪些项目最有效地偿还了您在开发方面的投资。

Pharma companies access and analyze this data as part of their decision-making process, they can more accurately predict which drugs in their pipeline offer the most promise with the least risk. These analysis tools allow decision-makers to make ‘apples to apples’ comparisons of one molecule against another, see the impact of different scenarios on timelines, revenue potential, and market uptake, and can even leverage the power of machine learning for deeper insights.

IQVIA’s管道架构师is a tool that pulls healthcare industry data from thousands of trials conducted across hundreds of indications. When users combine this industry data with their own internal data sets, they can forecast outcomes with a much higher degree of accuracy and make better portfolio selections.

COPD Development on a Budget

在许多情况下，客户使用Pipeline Architect工具为个人产品开发计划找到最佳的前进道路。使用数据，它们可以对单个项目方案进行建模并对各种开发路径进行排名以减轻风险并最大化结果。

考虑一个最新的项目，其中客户拥有成功完成2阶段的COPD产品，但最佳3阶段计划预算超过了其资源。他们需要确定哪种替代发展选项给出了给定时间和预算限制的最佳潜在途径。

客户的内部开发团队被要求迅速产生替代性较低的成本选择，以由内部治理机构审查。尽管他们能够为替代方案生成一系列修订的假设，但他们仍在努力衡量这些变化对管理时间，成本和监管成功的可能性的影响，并在管理层要求的短时间内。

They turned to IQVIA for help. Using管道架构师，IQVIA的专家对所需的指示进行了试验基准分析，并在两周内建立了20个潜在的临床开发计划方案。然后，他们根据预期批准日期，监管成功的概率，开发成本和风险调整的NPV对场景进行了排名。

这为团队提供了他们与他们的治理机构进行强有力的betway必威怎么提款，数据驱动的讨论所需的见解，并最终选择将带来最佳潜在市场结果的场景。

这只是正确的数据和分析如何将选择过程从受过教育的猜测转变为基于证据的决策的一个例子。

So the next time you are pondering which drug candidate to invest in or the best way to move a drug through development to commercialization, move beyond evaluating which PowerPoint is the most compelling. Use the power of big data and machine learning to give you the confidence that you are making the right choice for your business.

To learn more about IQVIA’s Pipeline Architect platform click这里or contact us atPipelineArchitect@iqvia.com。